{
    "prompt": "\n    If no matching FDA-approved drugs are found, please return message with the following JSON schema:\n    {\n        \"Status\": \"no_match\",\n        \"Message\": \"No drugs are FDA-approved for the provided context\"\n    }\n    \n    If FDA-approved drugs are found, please provide each treatment as a json format with the following JSON schema:\n    {\n        \"Status\": \"success\",\n        \"Treatment 1\": {\n            \"Disease Name\": ,\n            \"Disease Phase or Condition\": ,\n            \"Drug Name\": ,\n            \"Prior Treatment or Resistance Status\": ,\n            \"Genomic Features\": \n            \"FDA-approval status\":\n            \"Link to FDA-approved Label\":\n            }\n    }\n    Query: \n    The following is a summarized molecular profile from MSK-IMPACT.\n    Based on this profile, answer with the appropriate treatments for this patient in the format above.\n    Patient ID: P-0035127\nAge: 81\nGender: Female\nSample ID: P-0035127-T01-IM6\nGene Panel: IMPACT468\nCancer Type: Colorectal Adenocarcinoma\nSample Type: Metastasis\nTumor Purity: 60.0%\n=============\nDNA Variants:\nARID1A c.2161G>T (p.G721C) - in 20.00% of 678 reads\nEGFL7 c.638A>C (p.K213T) - in 23.00% of 684 reads\nEGFR c.1640G>A (p.R547K) - in 18.00% of 895 reads\nEPHA3 c.722G>A (p.R241K) - in 33.00% of 287 reads\nERBB4 c.3254C>G (p.T1085S) - in 11.00% of 779 reads\nKRAS c.180_181delinsAA (p.Q61K) - in 34.00% of 411 reads\nRNF43 c.349dup (p.R117Pfs*8) - in 43.00% of 1012 reads\nTP53 c.589G>A (p.V197M) - in 39.00% of 536 reads\nCNA Data:\nIGF2 - High Level Amplification\nCTLA4 - High Level Amplification\nTERT - High Level Amplification\nAGO2 - High Level Amplification\nStructural Variants:\nNo structural variant data found.\n    ",
    "response": "{\n  \"Status\": \"no_match\",\n  \"Message\": \"No drugs are FDA-approved for the provided context\"\n}"
}